STAT3 and B-cell chronic lymphocytic leukemia: Additionally, Kondo et al. showed that patients with chronic lymphocytic leukemia (CLL) who received ibrutinib exhibited significantly reduced STAT3 phosphorylation and IL-10 proinflammatory cytokine levels [15].